Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer

2Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.

Abstract

One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer. © 2013 Chen et al, publisher and licensee Dove Medical Press Ltd.

Cite

CITATION STYLE

APA

Chen, X. H., Li, Z. Q., Peng, H., Jin, S. M., Fu, H. Q., Zhu, T. C., & Weng, X. G. (2013). Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer. OncoTargets and Therapy, 6, 527–530. https://doi.org/10.2147/OTT.S44162

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free